Viral infections range from self-limiting to more serious and fatal infections; therefore, some viral infections are of great public health concern worldwide, e.g., Hepatitis B virus, Hepatitis C virus, and HIV. Recently, the world faced a new infection due to the coronavirus, COVID-19, which was announced as a pandemic in early 2020. This virus infected more than 500 million people, killing around 6 million people worldwide. On the other hand, the increase in drug-resistant strains is also creating serious health problems. Thus, developing new selective antiviral agents with a different mode of action to fight against mutated and novel viruses is a primary goal of many researchers. Taking into account the role of heterocyclic compounds in drug discovery as a key structural component of most of the bioactive molecules; herein, we report an extensive review of the antiviral activity of five-membered heterocyclic compounds reported from 2015 to date. In this review, the antiviral activities of the agents containing the specified ring systems thiadiazoles, triazoles, oxadiazoles, and thiazoles are discussed.
Keyphrases
- sars cov
- drug resistant
- hepatitis b virus
- public health
- hepatitis c virus
- drug discovery
- coronavirus disease
- human immunodeficiency virus
- multidrug resistant
- mental health
- healthcare
- antiretroviral therapy
- respiratory syndrome coronavirus
- acinetobacter baumannii
- escherichia coli
- hiv positive
- liver failure
- hiv testing
- hiv infected
- hiv aids
- risk assessment
- pseudomonas aeruginosa
- genetic diversity
- south africa
- human health
- health promotion